Wolf Susan M, Lawrenz Frances P, Nelson Charles A, Kahn Jeffrey P, Cho Mildred K, Clayton Ellen Wright, Fletcher Joel G, Georgieff Michael K, Hammerschmidt Dale, Hudson Kathy, Illes Judy, Kapur Vivek, Keane Moira A, Koenig Barbara A, Leroy Bonnie S, McFarland Elizabeth G, Paradise Jordan, Parker Lisa S, Terry Sharon F, Van Ness Brian, Wilfond Benjamin S
University of Minnesota, MN, USA.
J Law Med Ethics. 2008 Summer;36(2):219-48, 211. doi: 10.1111/j.1748-720X.2008.00266.x.
No consensus yet exists on how to handle incidental findings (IFs) in human subjects research. Yet empirical studies document IFs in a wide range of research studies, where IFs are findings beyond the aims of the study that are of potential health or reproductive importance to the individual research participant. This paper reports recommendations of a two-year project group funded by NIH to study how to manage IFs in genetic and genomic research, as well as imaging research. We conclude that researchers have an obligation to address the possibility of discovering IFs in their protocol and communications with the IRB, and in their consent forms and communications with research participants. Researchers should establish a pathway for handling IFs and communicate that to the IRB and research participants. We recommend a pathway and categorize IFs into those that must be disclosed to research participants, those that may be disclosed, and those that should not be disclosed.
对于如何处理人体研究中的偶然发现(IFs),目前尚无共识。然而,实证研究记录了广泛研究中的偶然发现,其中偶然发现是指超出研究目的、对个体研究参与者具有潜在健康或生殖重要性的发现。本文报告了一个由美国国立卫生研究院资助的为期两年的项目组的建议,该项目组旨在研究如何在基因和基因组研究以及成像研究中管理偶然发现。我们得出结论,研究人员有义务在其研究方案、与机构审查委员会(IRB)的沟通、知情同意书以及与研究参与者的沟通中,探讨发现偶然发现的可能性。研究人员应建立处理偶然发现的途径,并将其告知IRB和研究参与者。我们推荐一种途径,并将偶然发现分为必须向研究参与者披露的、可能披露的以及不应披露的三类。